Dr. Jamie Todd Caracciolo, MBA, MD

Dr. Caracciolo practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Caracciolo's NPI, 1740292804, was assigned on August 13, 2006. Dr. Caracciolo graduated from USF Health Morsani College of Medicine in 2001. Dr. Caracciolo holds Florida license ME98138.

Dr. Caracciolo's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Caracciolo also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Caracciolo's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dr. Caracciolo is also affiliated with AdventHealth Tampa. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Caracciolo to 2 more hospitals, 1 breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Caracciolo practices, 7 sites in all. Vendor and product names are available with a free account.

Diagnostic radiology is Dr. Caracciolo's primary specialty in the NPI Registry, under taxonomy code 2085R0202X. Dr. Caracciolo is board certified in diagnostic radiology by the American Board of Radiology. Dmand AI has Dr. Caracciolo's licenses on file in 4 states: Florida, Kentucky, Massachusetts and Missouri.

CMS data shows 1,723 Medicare services from Dr. Caracciolo across 34 procedure codes in 2024, for 1,095 Medicare patients. Medicare paid $70,105 for them.

CMS counts 1,095 Medicare patients who saw Dr. Caracciolo in 2024. The largest group is 65 to 74, with 494 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Caracciolo's median patient age at 65, with 53% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Caracciolo for performance year 2024, reported as part of a group. Dr. Caracciolo accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 31 papers to Dr. Caracciolo, published from 2010 to 2023. 2017 was the busiest year, with 5. The most frequent topics are Antineoplastic Agents, Diagnosis, Differential and Magnetic Resonance Imaging. Dr. Caracciolo has published most often in Radiol Case Rep. Dr. Caracciolo's most frequent co-authors are Marilyn Yuanxin Ma Bui, MD, Evita B. Henderson-Jackson, MD and David Cheong, MD.

Dmand AI links Dr. Caracciolo to 4 clinical trials. 2 are still active or recruiting. Conditions studied include Myositis Ossificans, Carcinoma, Non-Small-Cell Lung and Ossification, Heterotopic. Regeneron Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Caracciolo that name 5 trials.

CMS Open Payments shows 82 general payments to Dr. Caracciolo from 4 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 100% of the total. Pfizer Inc. paid the most, $126,895. It also lists 67 research payments totaling $64,525 from 2021 to 2025, naming 5 clinical trials.

Dr. Caracciolo graduated from USF Health Morsani College of Medicine in 2001.

Dr. Caracciolo is in network with 3 carriers, including Elevance, Molina and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.